Definition
CANDLE syndrome (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature) is a rare, hereditary autoinflammatory disorder characterized by recurrent fevers, distinctive skin lesions, progressive lipodystrophy, and systemic inflammation. The condition is associated with mutations in genes encoding components of the immunoproteasome, most commonly PSMB8.
Overview
First described in the early 2010s, CANDLE syndrome belongs to a group of interferonopathies—disorders driven by dysregulated type I interferon signaling. Patients typically present in infancy or early childhood with systemic symptoms that may persist lifelong. Due to its rarity, prevalence estimates are limited, but only a few dozen genetically confirmed cases have been reported in the medical literature. Management focuses on controlling inflammation and mitigating metabolic complications arising from lipodystrophy.
Etymology/Origin
The acronym CANDLE is derived from the principal clinical features observed in affected individuals:
- Chronic
- Atypical
- Neutrophilic Dermatosis
- Lipodystrophy
- Elevated temperature
The term was coined by researchers who identified the syndrome as a distinct clinical entity based on the combination of dermatologic, metabolic, and immunologic abnormalities.
Characteristics
| Feature | Description |
|---|---|
| Cutaneous manifestations | Persistent, violaceous or erythematous papules and plaques, often described as “neutrophilic dermatoses.” Lesions may be painful and can ulcerate. |
| Fever | Recurrent, daily or near‑daily spikes of high fever, typically without an identifiable infectious trigger. |
| Lipodystrophy | Progressive loss of subcutaneous adipose tissue, leading to a characteristic “muscular” appearance and metabolic disturbances such as insulin resistance and dyslipidemia. |
| Laboratory findings | Elevated inflammatory markers (ESR, CRP), increased serum ferritin, and a type I interferon signature detectable in peripheral blood. |
| Genetics | Autosomal recessive inheritance; pathogenic variants most frequently reported in PSMB8 (encoding the immunoproteasome β5i subunit). Rare cases involve other immunoproteasome-related genes (PSME1, POMP). |
| Systemic involvement | May include hepatosplenomegaly, anemia, growth retardation, and arthropathy. |
| Therapeutic approaches | Conventional immunosuppressants (e.g., corticosteroids) provide limited benefit. Targeted therapies such as Janus kinase (JAK) inhibitors (e.g., baricitinib, tofacitinib) have shown clinical improvement by dampening interferon signaling. |
Related Topics
- Interferonopathies – A broader class of disorders marked by aberrant type I interferon activity, including Aicardi‑Goutières syndrome and STING‑associated vasculopathy.
- Proteasome-associated autoinflammatory syndromes (PRAAS) – A group encompassing CANDLE syndrome and related conditions caused by mutations affecting proteasome subunits.
- Lipodystrophy – A spectrum of disorders characterized by abnormal or deficient adipose tissue distribution, with metabolic consequences.
- Janus kinase (JAK) inhibitors – Small‑molecule agents that block JAK‑STAT signaling, increasingly used in the treatment of refractory autoinflammatory diseases.
References for further reading:
- Liu Y et al. “Mutations in PSMB8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome.” Nat Genet. 2011.
- Wang Y et al. “JAK inhibition in CANDLE syndrome: clinical outcomes and interferon signature modulation.” J Clin Immunol. 2022.
- Ghosh R et al. “Proteasome-associated autoinflammatory syndromes: clinical and genetic insights.” Clin Immunol. 2020.